PILL Stock: Direxion Daily Pharmaceutical & Medical Bull 3X ETF Profile & Analysis (2026)
A high-leverage tactical tool seeking 300% daily returns of the S&P Pharmaceuticals Select Industry Index — Updated May 2026 with current AUM, expense ratio, holdings, and performance data.
PILL is a 3x leveraged ETF designed for aggressive traders seeking to capitalize on short-term upward momentum in the U.S. pharmaceutical sector. Unlike a standard healthcare stocks index fund, PILL utilizes swap agreements and financial derivatives to provide 300% the daily performance of the S&P Pharmaceuticals Select Industry Index. This exposure is strictly limited to drug manufacturers and pharmaceutical research firms, excluding insurers and medical device providers found in broader healthcare funds.
Investors must recognize that PILL is **not a long-term investment**. Because the fund resets its 3x leverage daily, it is subject to “volatility decay,” a mathematical phenomenon where compounding in a choppy market can erode capital even if the underlying index remains flat. Traders looking for similar high-octane exposure in the medical space often compare PILL with the LABU Stock Profile, which offers 3x leverage on the biotechnology sector. Due to its micro-cap status and low AUM, PILL requires the use of limit orders to navigate wider bid-ask spreads.
Key Takeaways — PILL Stock
Designed to deliver 3x the daily return of pharma stocks; returns over periods longer than one day will likely deviate significantly from 3x.
The daily reset mechanism makes this fund unsuitable for long-term holding due to the high risk of compounding losses and volatility decay.
Tracks an index that weights pharmaceutical giants like Eli Lilly and Pfizer roughly equally, reducing single-stock concentration risk.
With approximately $12M in AUM and thin daily volume, traders should use limit orders to avoid execution slippage.
PILL — Live Price Chart
Real-time chart from TradingView.
PILL ETF Vitals & Key Statistics
Core data as of May 2026.
| Data Point | Value | Data Point | Value |
|---|---|---|---|
| Full Name | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | Ticker | PILL |
| Issuer | Direxion (Rafferty Asset Management) | Asset Class | Leveraged Equity (Pharma) |
| Index Tracked | S&P Pharmaceuticals Select Industry Index | Structure | Open-Ended Fund |
| Expense Ratio | 0.95% | AUM | ~$12.32M |
| Inception Date | November 15, 2017 | Exchange | AMEX |
| No. of Holdings | ~62 | Dividend Yield | 0.57% |
| 52-Week High | $13.67 | 52-Week Low | $3.62 |
| Avg Daily Volume | ~105,360 shares | YTD Return | 30% |
| 1-Year Return | 148.16% | 5-Year Return | N/A (Significant Decay) |
| Category | Trading — Leveraged Equity | Dividend Frequency | Quarterly |
PILL Top 10 Holdings (May 2026)
PILL uses swaps to achieve leverage. Underlying equity weights are modified equal-weight (~1.5-2.0% each).
| Rank | Ticker | Company Name | Sector | Weight % |
|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co. | Pharmaceuticals | ~2.0% |
| 2 | ABBV | AbbVie Inc. | Pharmaceuticals | ~2.0% |
| 3 | BMY | Bristol-Myers Squibb | Pharmaceuticals | ~2.0% |
| 4 | PFE | Pfizer Inc. | Pharmaceuticals | ~2.0% |
| 5 | MRK | Merck & Co. | Pharmaceuticals | ~2.0% |
| 6 | JNJ | Johnson & Johnson | Pharmaceuticals | ~2.0% |
| 7 | REGN | Regeneron Pharmaceuticals | Pharmaceuticals | ~2.0% |
| 8 | ZTS | Zoetis Inc. | Pharmaceuticals | ~2.0% |
| 9 | – | S&P Pharma Index Swap (GS) | Derivatives | ~1.7% |
| 10 | – | S&P Pharma Index Swap (MS) | Derivatives | ~1.7% |
PILL — Pros & Cons
✓ High Intraday Potential
Allows traders to amplify gains during clear pharmaceutical sector uptrends or positive regulatory news.
✗ Severe Volatility Decay
The daily reset means that in non-trending markets, the fund will lose value even if the index is unchanged.
✓ Equal-Weight Benefit
Unlike cap-weighted funds, PILL gives substantial exposure to mid-cap pharma firms, not just the top 3 giants.
✗ High Management Fees
A 0.95% expense ratio is expensive, though typical for complex leveraged derivative-based ETFs.
✓ Tactical Hedging
Useful for sophisticated traders to hedge a bearish pharmaceutical portfolio position using small capital outlays.
✗ Liquidity Risks
Low AUM and volume lead to wider bid-ask spreads, making entry and exit potentially costly for larger trades.
Who Should Consider PILL?
Experienced day traders and tactical swing traders with a 24-hour to 48-hour outlook on pharma sector news.
Long-term buy-and-hold investors, retirement portfolios, or anyone unwilling to monitor their positions multiple times per day.
You are anticipating a sector-wide rally in biotechnology and pharma companies due to major policy shifts or FDA trends.
Standard taxable brokerage accounts where frequent trading is permitted. High-turnover strategies make this less ideal for some IRA structures.
PILL vs Similar ETFs
Key metrics comparison.
| ETF | Full Name | Expense Ratio | AUM | Holdings | Div Yield | YTD | Best For |
|---|---|---|---|---|---|---|---|
| PILL ★ | Daily Pharma Bull 3X ETF | 0.95% | $12.32M | ~62 | 0.57% | 30% | 3x Pharma Bull |
| PILS | Daily Pharma Bear 3X ETF | 0.95% | ~$2.5M | ~62 | 0.00% | Negative | 3x Pharma Bear |
| LABU | Daily Biotech Bull 3X ETF | 0.95% | ~$850M | ~80 | 0.12% | Volatile | 3x Biotech Bull |
| CURE | Daily Healthcare Bull 3X ETF | 0.95% | ~$400M | ~100 | 0.45% | Steady | Broad Healthcare |
PILL Technical Analysis
Real-time buy/sell signals.
PILL — Risks & Considerations
Compounding and Decay
Because the fund resets daily, mathematical decay will likely lead to total loss of capital if held over a long period of market volatility.
High Leverage Exposure
A 10% drop in the underlying pharma index could lead to a 30% or greater crash in PILL stock price in a single day.
Low AUM/Closure Risk
With only $12M in assets, PILL is a “micro-ETF” and faces the risk of fund liquidation if assets do not grow sufficiently.
Index Concentration
The fund is 100% exposed to the pharmaceutical industry, making it hypersensitive to drug pricing legislation and FDA decisions.